Sarepta Therapeutics Aktie
WKN DE: A1J1BH / ISIN: US8036071004
18.12.2015 13:32:21
|
Sarepta: FDA Advisory Committee To Review NDA For Eteplirsen - Quick Facts
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) announced the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA will review the company's New Drug Application (NDA) for eteplirsen, on January 22, 2016. Eteplirsen is designed to address the underlying cause of Duchenne Muscular Dystrophy by restoring the messenger RNA reading frame, thus enabling the production of a shorter, functional form of the dystrophin protein.
The PDUFA action date for completion of FDA review of the eteplirsen NDA is February 26, 2016.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sarepta Therapeutics Inc.mehr Nachrichten
05.11.24 |
Ausblick: Sarepta Therapeutics präsentiert Quartalsergebnisse (finanzen.net) |
Analysen zu Sarepta Therapeutics Inc.mehr Analysen
Aktien in diesem Artikel
Sarepta Therapeutics Inc. | 52,92 | 0,04% |
|